The Office of Pharmaceutical Quality in the US Food and Drug Administration’s Center for Drug Evaluation and Research 8 April laid out its case for rating industry on what the agency calls quality management maturity so that manufacturers will work harder to ensure a stable supply of quality pharmaceuticals.
The pitch made in the agency's new white paper on the topic is that high-quality pharmaceutical manufacturers would benefit from recognition and reward, while the people who buy, dispense and use their products would
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?